flurry of new versions of known drugs is entering psychiatry. These new drugs are made by removing 1 mirror-image stereoisomer from a mixture of 2 contained in the original drug-a strategy that may lead to some improvements over the originals.
The story is perhaps best exemplified by levodopa, developed years ago for the treatment of Parkinson's disease (Table 1) . Levodopa, a dopamine precursor, comes in 2 different 3-dimensional forms, but only l version is active. 1 Not until the dextro form was removed could progress be made in using this agent for Parkinson's disease, because side effects, some quite serious, limited the utility of the racemic mixture. Several other agents in the fields of psychopharmacology, gastroenterology, allergy, and various therapeutic areas are recognized as racemic mixtures, sometimes called R and S (or recto and sinister), sometimes D and L (or dextro and levo), sometimes + and - (Figure 1 ). Examples of recent attempts to improve the original drug (Table 1) show that this approach is sometimes but not always successful. Because some selective enantiomers are substantial improvements over racemic mixtures, new drugs are now rarely developed as racemic mixtures. Improvements are illustrated in Figures 2 and 3 , and can range from lessened side effects, to reduced drug interactions (Figure 2) , to better efficacy including a better relationship between efficacy and a reduced drug dose (Figure 3) ♦ Old drugs that exist as racemic mixtures are increasingly being relaunched with the inactive isomer removed.
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♦ Single isomer drugs can be preferable if they allow reduction in dosage, improved therapeutic efficacy, better relationship between dose and therapeutic effects, fewer side effects, and reduced drug interactions. 
